49B:F:F-BeiGene Ltd. (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 11.4

Change

0.00 (0.00)%

Market Cap

USD 16.61B

Volume

192.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOV:F Novo Nordisk A/S

N/A

USD 526.04B
NOVA:F Novo Nordisk A/S

N/A

USD 524.27B
RGO:F Regeneron Pharmaceuticals Inc

N/A

USD 117.89B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 91.04B
CSJ:F CSL Limited

N/A

USD 91.04B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 31.06B
DUL:F Alnylam Pharmaceuticals Inc

N/A

USD 30.44B
1AE:F Argen-X

N/A

USD 29.24B
1AEA:F argenx SE

N/A

USD 29.18B
0QF:F Moderna Inc

N/A

USD 25.22B

ETFs Containing 49B:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.06% 52% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.06% 51% F 32% F
Trailing 12 Months  
Capital Gain -20.83% 49% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.83% 48% F 27% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.03% 44% F 23% F
Dividend Return -9.03% 44% F 22% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.00% 62% D 45% F
Risk Adjusted Return -32.27% 49% F 30% F
Market Capitalization 16.61B 98% N/A 90% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.